Company news
Citius Oncology, Inc. (NASDAQ:CTOR) news
Every Citius Oncology, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
August 14, 2026
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri
August 12, 2026
Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment
August 5, 2026
Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption
July 21, 2026
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pem...
June 1, 2026
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annua...
May 26, 2026
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
May 15, 2026
Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization
May 5, 2026
Citius Oncology Ships First International Order of LYMPHIR™ to Europe
April 29, 2026
Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules
April 24, 2026
Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development
March 31, 2026
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts
March 24, 2026
Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizuma...
March 10, 2026
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in Hig...
March 4, 2026
Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program
February 24, 2026
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
February 13, 2026
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
February 13, 2026
Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar
February 11, 2026
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
December 23, 2025
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
December 23, 2025
Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under N...
December 10, 2025
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
December 9, 2025
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim
December 4, 2025
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)
December 1, 2025
Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting
November 25, 2025
Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration
November 21, 2025
Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules
October 21, 2025
Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch
October 20, 2025
Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences
October 17, 2025
Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™
October 16, 2025
Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe
October 7, 2025
Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement
September 10, 2025
Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement
September 9, 2025
Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch
August 22, 2025
Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update
August 12, 2025
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update
August 12, 2025
Citius Oncology Announces Closing of $9.0 Million Public Offering
July 17, 2025
Citius Oncology Announces Pricing of $9.0 Million Public Offering
July 16, 2025
Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora
July 15, 2025
Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
July 8, 2025
Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025
June 17, 2025
Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules
June 10, 2025
Citius Oncology Enters into Distribution Services Agreement with Cardinal Health
June 9, 2025
Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update
May 14, 2025
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update
May 14, 2025
Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
May 5, 2025
Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock
April 1, 2025
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update
February 14, 2025
Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update
February 14, 2025
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services
February 6, 2025